Long-Acting Bronchodilators and Arterial Stiffness in Patients With COPD: A Comparison of Fluticasone Furoate/Vilanterol With Tiotropium

Chest

Volumn 146, Issue 6, 2014, Pages 1521-1530

  Pepin, Jean Louis ^a   Cockcroft, John R ^b   Midwinter, Dawn ^c   Sharma, Sanjay ^d   Rubin, David B ^d   Andreas, Stefan ^e  

^a UNIV GRENOBLE ALPES   (France)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE FUROATE PLUS VILANTEROL; SALBUTAMOL; TIOTROPIUM BROMIDE; ANDROSTANE DERIVATIVE; BENZYL ALCOHOL DERIVATIVE; BRONCHODILATING AGENT; CHLOROBENZENE; DELAYED RELEASE FORMULATION; FLUTICASONE FUROATE; SCOPOLAMINE DERIVATIVE; VILANTEROL;

ADULT; AGED; ARTERIAL STIFFNESS; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BRONCHITIS; CARDIOVASCULAR DISEASE; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY POWDER INHALER; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HAND FRACTURE; HEADACHE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MEDICAL HISTORY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POST HOC ANALYSIS; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SMOKING; SUPRAVENTRICULAR PREMATURE BEAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VITAL SIGN; CLINICAL TRIAL; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; MIDDLE AGED; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; AGED; ANDROSTADIENES; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULSE WAVE ANALYSIS; RESPIRATORY FUNCTION TESTS; SCOPOLAMINE DERIVATIVES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASCULAR STIFFNESS;

EID: 84925284101     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-2859     Document Type: Article

References (41)

1. 1 Sin, DD, Van Eeden, S, Leipsic, J, Man, SF, Reply: beneficial effects of angiotensin receptor blockade in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 187(3), 2013, 328.
2. 2 Decramer, M, Janssens, W, Miravitlles, M, Chronic obstructive pulmonary disease. Lancet 379:9823 (2012), 1341–1351.
3. 3 Divo, M, Cote, C, de Torres, JP, et al. BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 186:2 (2012), 155–161.
4. 4 Stone, IS, Barnes, NC, Petersen, SE, Chronic obstructive pulmonary disease: a modifiable risk factor for cardiovascular disease?. Heart 98:14 (2012), 1055–1062.
5. 5 Lee, HM, Lee, J, Lee, K, Luo, Y, Sin, DD, Wong, ND, Relation between COPD severity and global cardiovascular risk in US adults. Chest 142:5 (2012), 1118–1125.
6. 6 Laurent, S, Alivon, M, Beaussier, H, Boutouyrie, P, Aortic stiffness as a tissue biomarker for predicting future cardiovascular events in asymptomatic hypertensive subjects. Ann Med 44:suppl 1 (2012), S93–S97.
7. 7 McAllister, DA, Maclay, JD, Mills, NL, et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176:12 (2007), 1208–1214.
8. 8 Sabit, R, Bolton, CE, Edwards, PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175:12 (2007), 1259–1265.
9. 9 Fabbri, LM, Luppi, F, Beghé, B, Rabe, KF, Complex chronic comorbidities of COPD. Eur Respir J 31:1 (2008), 204–212.
10. 10 Macnee, W, Maclay, J, McAllister, D, Cardiovascular injury and repair in chronic obstructive pulmonary disease. Proc Am Thorac Soc 5:8 (2008), 824–833.
11. 11 Vivodtzev, I, Tamisier, R, Baguet, JP, Borel, JC, Levy, P, Pépin, JL, Arterial stiffness in COPD. Chest 145:4 (2014), 861–875.
12. 12 Dransfield, MT, Cockcroft, JR, Townsend, RR, et al. Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD. Respir Med 105:9 (2011), 1322–1330.
13. 13 Calverley, PM, Anderson, JA, Celli, B, et al. TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax 65:8 (2010), 719–725.
14. 14 Löfdahl, CG, Postma, DS, Pride, NB, Boe, J, Thorén, A, Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur Respir J 29:6 (2007), 1115–1119.
15. 15 Dong, YH, Lin, HH, Shau, WY, Wu, YC, Chang, CH, Lai, MS, Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 68:1 (2013), 48–56.
16. 16 ICH tripartite guideline: guidance for good clinical practice E6 (R1). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use website. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf, 2014 Accessed July 24.
17. 17 WMA declaration of Helsinki—ethical principles for medical research involving human subjects. World Medical Association, Inc website. http://www.wma.net/en/30publications/10policies/b3/index.html, 2008 Updated October. Accessed July 24, 2014.
18. 18 Sin, DD, MacNee, W, Chronic obstructive pulmonary disease and cardiovascular diseases: a “vulnerable” relationship. Am J Respir Crit Care Med 187:1 (2013), 2–4.
19. 19 Rutten, FH, Hoes, AW, Chronic obstructive pulmonary disease: a slowly progressive cardiovascular disease masked by its pulmonary effects?. Eur J Heart Fail 14:4 (2012), 348–350.
20. 20 Laurent, S, Cockcroft, J, Van Bortel, L, et al. European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27:21 (2006), 2588–2605.
21. 21 Ben-Shlomo, Y, Spears, M, Boustred, C, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 63:7 (2014), 636–646.
22. 22 Brunner, EJ, Shipley, MJ, Witte, DR, et al. Arterial stiffness, physical function, and functional limitation: the Whitehall II Study. Hypertension 57:5 (2011), 1003–1009.
23. 23 Duprez, DA, Hearst, MO, Lutsey, PL, et al. Associations among lung function, arterial elasticity, and circulating endothelial and inflammation markers: the multiethnic study of atherosclerosis. Hypertension 61:2 (2013), 542–548.
24. 24 Wimmer, NJ, Townsend, RR, Joffe, MM, Lash, JP, Go, AS, Chronic Renal Insufficiency Cohort Study Investigators. Correlation between pulse wave velocity and other measures of arterial stiffness in chronic kidney disease. Clin Nephrol 68:3 (2007), 133–143.
25. 25 McEniery, CM, Yasmin, Hall, IR, Qasem, A, Wilkinson, IB, Cockcroft, JR, ACCT Investigators. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol 46:9 (2005), 1753–1760.
26. 26 Townsend, RR, Wimmer, NJ, Chirinos, JA, et al. Aortic PWV in chronic kidney disease: a CRIC ancillary study. Am J Hypertens 23:3 (2010), 282–289.
27. 27 Mahmud, A, Feely, J, Effect of smoking on arterial stiffness and pulse pressure amplification. Hypertension 41:1 (2003), 183–187.
28. 28 Doonan, RJ, Hausvater, A, Scallan, C, Mikhailidis, DP, Pilote, L, Daskalopoulou, SS, The effect of smoking on arterial stiffness. Hypertens Res 33:5 (2010), 398–410.
29. 29 Maclay, JD, McAllister, DA, Rabinovich, R, et al. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax 67:7 (2012), 606–612.
30. 30 Reference Values for Arterial Stiffness' Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J 31:19 (2010), 2338–2350.
31. 31 Albarrati, AM, Gale, NS, Munnery, MM, et al. Rapid progression of central arterial stiffness in COPD: preliminary 2 year follow-up data from the ARCADE study. J Am Soc Hypertens 8:4 (2014), e4–e5.
32. 32 Vestbo, J, Anderson, J, Brook, RD, et al. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Eur Respir J 41:5 (2013), 1017–1022.
33. 33 Wilkinson, IB, McEniery, CM, Schillaci, G, et al. ARTERY Society guidelines for validation of non-invasive haemodynamic measurement devices: part 1, arterial pulse wave velocity. Artery Res 4:2 (2010), 34–40.
34. 34 Weber, T, Ammer, M, Rammer, M, et al. Noninvasive determination of carotid-femoral pulse wave velocity depends critically on assessment of travel distance: a comparison with invasive measurement. J Hypertens 27:8 (2009), 1624–1630.
35. 35 Dinenno, FA, Jones, PP, Seals, DR, Tanaka, H, Age-associated arterial wall thickening is related to elevations in sympathetic activity in healthy humans. Am J Physiol Heart Circ Physiol 278:4 (2000), H1205–H1210.
36. 36 Swierblewska, E, Hering, D, Kara, T, et al. An independent relationship between muscle sympathetic nerve activity and pulse wave velocity in normal humans. J Hypertens 28:5 (2010), 979–984.
37. 37 Andreas, S, Anker, SD, Scanlon, PD, Somers, VK, Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest 128:5 (2005), 3618–3624.
38. 38 Fatouleh, R, Macefield, VG, Respiratory modulation of muscle sympathetic nerve activity is not increased in essential hypertension or chronic obstructive pulmonary disease. J Physiol 589:Pt 20 (2011), 4997–5006.
39. 39 Macklem, PT, Therapeutic implications of the pathophysiology of COPD. Eur Respir J 35:3 (2010), 676–680.
40. 40 Crim, C, Calverley, PM, Anderson, JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 34:3 (2009), 641–647.
41. 41 Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD website. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jun11.pdf, 2013 Updated. Accessed July 24, 2014.